Keybank National Association OH Purchases 1,701 Shares of Thermo Fisher Scientific Inc. $TMO

Keybank National Association OH boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 292,395 shares of the medical research company’s stock after buying an additional 1,701 shares during the period. Keybank National Association OH owned approximately 0.08% of Thermo Fisher Scientific worth $169,428,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in TMO. JPL Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific during the 3rd quarter valued at approximately $28,000. Beacon Financial Strategies CORP bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $29,000. Olistico Wealth LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at $29,000. Cloud Capital Management LLC bought a new position in Thermo Fisher Scientific during the third quarter valued at $31,000. Finally, KERR FINANCIAL PLANNING Corp purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth $38,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.6%

NYSE:TMO opened at $470.75 on Wednesday. The firm has a 50 day moving average of $497.78 and a 200 day moving average of $548.77. The stock has a market capitalization of $174.94 billion, a price-to-earnings ratio of 25.88, a PEG ratio of 2.07 and a beta of 0.97. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same period last year, the business posted $5.15 earnings per share. The firm’s revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 24.83 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date was Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Insider Activity

In related news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the sale, the executive vice president owned 20,752 shares in the company, valued at approximately $11,230,982.40. This trade represents a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is owned by company insiders.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 beat and raised/clear FY guidance — Thermo Fisher reported fiscal Q1 revenue of $11.01B (+6% YoY) and an EPS beat, with FY 2026 EPS guidance set at $24.64–$25.12 (analyst consensus ~$24.83). The results reinforce underlying profitability and give investors a forward earnings framework. Read More.
• Positive Sentiment: Investment in bioprocessing capacity — Thermo Fisher opened a flagship U.S. Bioprocess Design Center in Plainville, MA to accelerate biologics process development and scale-up, which supports higher-growth bioprocess/biologics end markets. This aligns with management’s focus on life-science tools and biologics services that command premium growth and margins. Read More.
• Neutral Sentiment: Investor Day scheduled for May 20 — Management will host Investor Day in NYC, giving investors an opportunity to get more detail on strategy, portfolio priorities, and medium-term targets; this event could catalyze forward guidance or strategic disclosures. Read More.
• Neutral Sentiment: “Buys into Astorg” mention — A report suggests some form of financial or strategic tie between Thermo Fisher and Astorg around the microbiology transaction; details are sparse, so investors should treat this as informational until clarified. Read More.
• Negative Sentiment: Sale of microbiology business to Astorg (~$1.075–1.08B) — Thermo Fisher agreed to sell its microbiology/IVD-related unit to private equity firm Astorg for roughly $1.075–$1.08B (including a $50M seller note). The unit generated roughly $645M revenue in 2025. Market takes are mixed: proceeds and sharper portfolio focus are positives, but the multiple implied by the sale and the move away from certain IVD exposures could worry investors who favor recurring diagnostic revenues. Astorg plans to accelerate growth (including M&A) for the spun-off business. Read More.

Analyst Ratings Changes

Several brokerages have recently issued reports on TMO. Wells Fargo & Company set a $683.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Robert W. Baird decreased their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Barclays dropped their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Morgan Stanley reiterated an “overweight” rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday. Finally, UBS Group reissued a “neutral” rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $623.05.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.